144 related articles for article (PubMed ID: 20532801)
1. Long-term remission of nephrotic syndrome with etanercept for concomitant juvenile idiopathic arthritis.
Ito S; Tsutsumi A; Harada T; Inaba A; Fujinaga S; Kamei K
Pediatr Nephrol; 2010 Oct; 25(10):2175-7. PubMed ID: 20532801
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of TNF-alpha antagonists in children with juvenile idiopathic arthritis who started treatment under 4 years of age.
Giménez-Roca C; Iglesias E; Torrente-Segarra V; Bou R; Sánchez-Manubens J; Calzada-Hernández J; Hernández S; Ricart S; Antón J
Rheumatol Int; 2015 Feb; 35(2):323-6. PubMed ID: 25086629
[TBL] [Abstract][Full Text] [Related]
3. Clinical remission in juvenile idiopathic arthritis after termination of etanercept.
Postępski J; Kobusińska K; Olesińska E; Osińska V; Opoka-Winiarska V
Rheumatol Int; 2013 Oct; 33(10):2657-60. PubMed ID: 22821261
[TBL] [Abstract][Full Text] [Related]
4. Factors associated with treatment response to etanercept in juvenile idiopathic arthritis.
Otten MH; Prince FH; Armbrust W; ten Cate R; Hoppenreijs EP; Twilt M; Koopman-Keemink Y; Gorter SL; Dolman KM; Swart JF; van den Berg JM; Wulffraat NM; van Rossum MA; van Suijlekom-Smit LW
JAMA; 2011 Dec; 306(21):2340-7. PubMed ID: 22056397
[TBL] [Abstract][Full Text] [Related]
5. Infection of an urachal cyst during etanercept therapy in juvenile idiopathic arthritis.
Holl-Wieden A; Beer M; Marx A; Bonfig R; Tappe D; Girschick HJ
Rheumatol Int; 2008 Jun; 28(8):819-22. PubMed ID: 18193232
[TBL] [Abstract][Full Text] [Related]
6. Attainment of inactive disease status following initiation of TNF-α inhibitor therapy for juvenile idiopathic arthritis: enthesitis-related arthritis predicts persistent active disease.
Donnithorne KJ; Cron RQ; Beukelman T
J Rheumatol; 2011 Dec; 38(12):2675-81. PubMed ID: 22089470
[TBL] [Abstract][Full Text] [Related]
7. Lipid profiles alter from pro-atherogenic into less atherogenic and proinflammatory in juvenile idiopathic arthritis patients responding to anti TNF-α treatment.
Yeh KW; Lee CM; Chang CJ; Lin YJ; Huang JL
PLoS One; 2014; 9(6):e90757. PubMed ID: 24603504
[TBL] [Abstract][Full Text] [Related]
8. Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label study.
Lahdenne P; Vähäsalo P; Honkanen V
Ann Rheum Dis; 2003 Mar; 62(3):245-7. PubMed ID: 12594111
[TBL] [Abstract][Full Text] [Related]
9. A follow-up study of patients with juvenile idiopathic arthritis who discontinued etanercept due to disease remission.
Pratsidou-Gertsi P; Trachana M; Pardalos G; Kanakoudi-Tsakalidou F
Clin Exp Rheumatol; 2010; 28(6):919-22. PubMed ID: 21205467
[TBL] [Abstract][Full Text] [Related]
10. Genomic characterization of remission in juvenile idiopathic arthritis.
Jiang K; Frank M; Chen Y; Osban J; Jarvis JN
Arthritis Res Ther; 2013 Aug; 15(4):R100. PubMed ID: 24000795
[TBL] [Abstract][Full Text] [Related]
11. Guidelines on the use of etanercept for juvenile idiopathic arthritis in Japan.
Yokota S; Mori M; Imagawa T; Murata T; Tomiita M; Itoh Y; Fujikawa S; Takei S;
Mod Rheumatol; 2010 Apr; 20(2):107-13. PubMed ID: 20087751
[TBL] [Abstract][Full Text] [Related]
12. Etanercept reduces matrix metalloproteinase-9 level in children with polyarticular juvenile idiopathic arthritis and TNF-alpha-308GG genotype.
Basic J; Pavlovic D; Jevtovic-Stoimenov T; Vojinovic J; Susic G; Stojanovic I; Kocic G; Milosevic V; Cvetkovic T; Marinkovic M; Veljkovic A
J Physiol Biochem; 2010 Jun; 66(2):173-80. PubMed ID: 20596903
[TBL] [Abstract][Full Text] [Related]
13. Switching the therapy from etanercept to infliximab in a child with rheumatoid factor positive polyarticular juvenile idiopathic arthritis.
Nerome Y; Imanaka H; Nonaka Y; Takei S
Mod Rheumatol; 2007; 17(6):526-8. PubMed ID: 18084710
[TBL] [Abstract][Full Text] [Related]
14. TNF and LT binding capacities in the plasma of arthritis patients: effect of etanercept treatment in juvenile idiopathic arthritis.
Gudbrandsdottir S; Larsen R; Sørensen LK; Nielsen S; Hansen MB; Svenson M; Bendtzen K; Müller K
Clin Exp Rheumatol; 2004; 22(1):118-24. PubMed ID: 15005015
[TBL] [Abstract][Full Text] [Related]
15. Rheumatoid arthritis and renal light-chain deposition disease: long-term effectiveness of TNF-α blockade with etanercept.
Cavagna L; Sepe V; Bobbio-Pallavicini F; Mangione F; Caporali R; Montecucco C
Int Urol Nephrol; 2011 Sep; 43(3):909-12. PubMed ID: 20559723
[TBL] [Abstract][Full Text] [Related]
16. The 'head-to-head' comparison of etanercept and infliximab in treating children with juvenile idiopathic arthritis.
Lamot L; Bukovac LT; Vidovic M; Frleta M; Harjacek M
Clin Exp Rheumatol; 2011; 29(1):131-9. PubMed ID: 21345300
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of etanercept and adalimumab in children aged 2 to 4 years with juvenile idiopathic arthritis.
Windschall D; Horneff G
Clin Rheumatol; 2016 Dec; 35(12):2925-2931. PubMed ID: 27709443
[TBL] [Abstract][Full Text] [Related]
18. Etanercept (Enbrel) in the treatment of juvenile idiopathic arthritis.
Berard RA; Laxer RM
Expert Opin Biol Ther; 2013 Nov; 13(11):1623-30. PubMed ID: 24070010
[TBL] [Abstract][Full Text] [Related]
19. Short and long-term immunogenicity and safety following the 23-valent polysaccharide pneumococcal vaccine in juvenile idiopathic arthritis patients under conventional DMARDs with or without anti-TNF therapy.
Aikawa NE; França IL; Ribeiro AC; Sallum AM; Bonfa E; Silva CA
Vaccine; 2015 Jan; 33(5):604-9. PubMed ID: 25554240
[TBL] [Abstract][Full Text] [Related]
20. Coexistence of familial Mediterranean fever and juvenile idiopathic arthritis with osteoporosis successfully treated with etanercept.
Kaya S; Kaptanoglu E; Elden H; Hizmetli S
Intern Med; 2010; 49(6):619-22. PubMed ID: 20228604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
